Marketing Feasibility Study of Ambrisenten

Abstract

Objective: The purpose of this study to exarmne the efficacy and safety doses of ambrisentan in patient with pulmonary arterial hypertension. Background: Pulmonary arterial hypertension is a life threatening and progressive diseases with limited treatment option. Endothelin is a vasoconstrictor and smooth muscle cell mitogen (that plays critical role in the pathogens and progression of P AH. Methods: In this regard the writer uses different methods collection of data from different sources. The writer uses books, journal, internet, company visits (RENET A) for IMS data. Result: There are five drugs available in the international market for the treatment of P AH. By comprising all the drugs it is found that Ambrisentan is better than all others. Conclusion: Ambrisentan appears to improve exercise capacity, symptom, and hem dynamics in patients with pulmonary arterial hypertension . The incidence and severity of liver enzyme abnormalities appears to low.